Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open‐label phase 3 results

Questionnaire‐based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries

(2020) Koremasa Hayama et al.   JOURNAL OF DERMATOLOGY

Clinical manifestations and quality of life in hidradenitis suppurativa patients: survey of participants from an internet support group

(2019) Isabel Greco Tavora et al.   ANAIS BRASILEIROS DE DERMATOLOGIA

Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa

(2019) Akimichi Morita et al.   JOURNAL OF DERMATOLOGY

Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data

(2019) Jessica Marvel et al.   BMJ Open

Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials

(2019) H.H. Zee et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

(2018) Caitriona Ryan et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

(2018) Christos C. Zouboulis et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

026 Nationwide investigation of hidradenitis suppurativa in Japan

(2017) K. Hayama et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

(2017) Amit Garg et al.   JAMA Dermatology

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

(2016) Alexa B. Kimball et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation

(2015) Christos C. Zouboulis et al.   DERMATOLOGY

Questionnaire surveillance of hidradenitis suppurativa in Japan

(2015) Ichiro Kurokawa et al.   JOURNAL OF DERMATOLOGY

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

(2015) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Incidence of Hidradenitis Suppurativa and Associated Factors: A Population-Based Study of Olmsted County, Minnesota

(2012) Benjamin G. Vazquez et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Hidradenitis Suppurativa

(2010) F. William Danby et al.   DERMATOLOGIC CLINICS

Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity

(2009) K. Sartorius et al.   BRITISH JOURNAL OF DERMATOLOGY

Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies

(2008) Jean E. Revuz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY